Squarepoint
IMRX icon

Squarepoint’s Immuneering IMRX Stock Holding History

Squarepoint’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$90.3K Sell
22,063
-35,626
-62% -$168K ﹤0.01% 4227
2026
Q2 		$288K Sell
57,689
-168,357
-74% -$852K ﹤0.01% 3839
2026
Q1 		$1.19M Buy
226,046
+133,790
+145% +$686K ﹤0.01% 2626
2025
Q4 		$607K Buy
+92,256
New +$592K ﹤0.01% 3054
2024
Q3 		– Sell
-24,262
Closed -$31.1K – 4370
2024
Q2 		$31.1K Buy
+24,262
New +$39.9K ﹤0.01% 3941

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Summit Financial
Summit Financial Parsippany, New Jersey $9.42B AUM 19.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Squarepoint's IMRX Position: Q3 2026 in Review

Squarepoint reduced its Immuneering (IMRX) stake by 62% in Q3 2026, selling an estimated $168K and leaving 22,063 shares worth $90.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

Squarepoint first reported a position in IMRX in Q2 2024 and has held it in 5 quarters since. The position peaked at $1.19M in Q1 2026. 72 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Squarepoint held 22,063 shares of Immuneering worth $90.3K as of Q3 2026.
  • Squarepoint sold 35,626 Immuneering shares in Q3 2026, an estimated $168K.
  • Immuneering made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4227 holding.
  • Squarepoint first reported a position in Immuneering in Q2 2024 and has held it in 5 quarters since.
  • Squarepoint's Immuneering position peaked at $1.19M in Q1 2026.
  • 72 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.